Treatment of gastroenteritis in COVID-19 children
Abstract
SARS-CoV-2 is highly contagious and has resulted in a rapid pandemic of COVID-19 that posing a threat to public health. They are causing a severe acute respiratory syndrome and known to infect the neurological, enteric, and hepatic systems. The aim of this document is to provide recommendations for a systematic approach for the gastroenteritis treatment in COVID-19 children where most important treatment options where discussed.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.